Dosing and administration dosage of recarbrio 1. combination of imipenem ( imi), a carbapenem antibiotic, cilastatin ( renal dehydropeptidase inhibitor) and relebactam ( rel) a beta- lactamase inhibitor • mechanism of action: o imi: inhibition of penicillin binding proteins ( pbps), leading to the disruption of bacterial cell wall synthesis. recarbrio ( imipenem, cilastatin, and relebactam) for injection is an antibacterial combination product consisting of imipenem, a carbapenem antibacterial drug, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a diazabicyclooctane beta lactamase inhibitor, for intravenous administration. recarbrio ( imipenem, cilastatin, and relebactam) for injection, 1. more imipenem cilastatin relebactam images. a for disk diffusion, use paper disks impregnated with imipenem/ relebactam at a concentration of 10/ 25 mcg/ ml. the additional indication in habp/ imipenem cilastatin relebactam vabp is based on results of the pivotal phase 3 restore- imi 2 trial that compared recarbrio 1.
objective: to provide a review of 3 novel antimicrobial agents— ceftazidime- avibactam, meropenem- vaborbactam, and imipenem/ cilastatin- relebactam— regarding treatment of klebsiella pneumoniae carbapenemase- producing enterobacterales ( kpc). 25 g ( imipenem 500 mg, cilastatin 500 mg, relebactam 250 mg) as directed above, then withdraw and discard excess solution as follows:. the drug builds on imipenem- cilastatin ( primaxin, a carbapenem that has been in use for more than 30 years) by the addition of relebactam, a novel beta- lactamase inhibitor in the diazabicyclooctane class. 75 grams ( imipenem 300mg, cilastatin 300mg, and relebactam 150mg) every 6 hours 15 to 29 0. the recommended dosage is 1 g ( imipenem 400 mg, cilastatin 400 mg, and relebactam 200 mg) every 6 hours in patients with a cl cr of 60 to 89 ml/ min; 0. 60 to 89 1 gram ( imipenem 400 mg, cilastatin 400 mg, and relebactam 200 mg) every 6 hours 30 to 59 0. 5 grams ( imipenem 200 mg, cilastatin 200 mg, and relebactam 100 mg) every 6 hours. 75 grams ( imipenem 300 mg, cilastatin 300 mg, and relebactam 150 mg) every 6 hours 15 to 29 0.
recarbrio is a combination of imipenem/ cilastatin and relebactam. imipenem, cilastatin, and relebactam combination injection is used to treat complicated bacterial infections in many different parts imipenem cilastatin relebactam of the body ( eg, kidneys, stomach). the most common adverse reactions include nausea, diarrhea, headache, fever an. at study entry open label linezolid 600 mg will also be administered by iv every 12 hours for up to 14 days. kaye ks, boucher hw, brown ml, aggrey a, khan i, joeng hk, tipping rw, du j, young k, butterton jr, paschke a. b clinical efficacy was shown for klebsiella aerogenes, enterobacter cloacae,. imipenem, cilastatin, and relebactam injection comes as a powder to be mixed with liquid and injected intravenously ( into a vein) over a period of 30 minutes. formulary resources available on full site. imipenem, cilastatin sodium, and relebactam is a fixed combination of imipenem ( a penem antibacterial), cilastatin ( a renal dehydropeptidase inhibitor), and relebactam ( a β- lactamase inhibitor) indicated for the treatment of complicated urinary tract infections ( cuti), including pyelonephritis, and complicated intra- abdominal infections ( ciai) caused by susceptible gram- negative bacteria in patients 18 years of age and older who have limited or no alternative treatment options. in, it was approved for use in the united states for the treatment of complicated urinary tract and complicated intra- abdominal infections.
official guidance on the appropriate use of antibiotics should be considered when using the medicine. recarbrio contains the active substances imipenem, cilastatin and relebactam. infections caused by bacteria classed as aerobic gram- negative bacteria when other treatments might not work. imipenem, cilastatin, and relebactam is a combination medicine that is used to treat complicated infections of the urinary tract ( bladder and kidneys) or infections within the stomach area ( abdomen). imipenem/ cilastatin and relebactam) ( mg) b dosing interval 60 to 89 1 gram ( imipenem 400mg, cilastatin 400mg, and relebactam 200mg) every 6 hours 30 to 59 0. imipenem/ cilastatin + relebactam ( 250 or 125 mg) was as effective as imipenem/ cilastatin alone for treatment of cuti. 75 g ( imipenem 300 mg, cilastatin 300 mg, and relebactam 150 mg) every 6 hours in patients with a cl cr of 30 to 59 ml/ min; and 0. fixed dose combination of a beta- lactamase inhibitor, with a carbapenem ( imipenem) and an enzyme inhibitor which blocks renal metabolism of imipenem ( cilastatin). for a list of compatible infusion bags and infusion sets— consult product literature.
25 grams is supplied as a white to light yellow sterile powder for constitution in a single- dose glass vial containing imipenem 500 mg ( equivalent to 530 mg imipenem monohydrate), cilastatin 500 mg ( equivalent to 531 mg cilastatin sodium), and relebactam 250 mg ( equivalent to 263. it is noteworthy that, since several antimicrobials were previously reported to be incompatible with imipenem/ cilastatin ( amphotericin b cholesteryl, amphotericin b lipid complex, amphotericin b liposome, ceftriaxone, daptomycin, ganciclovir, minocycline, quinupristin and dalfopristin, sulfamethoxazole- trimethoprim and temocillin), they were. minimal accumulation of imipenem, cilastatin or relebactam was observed following multiple 30- minute intravenous infusions of relebactam ( 50 to 625 mg) co- administered with 500 mg imipenem/ 500 mg cilastatin every 6 hours up to 7 days in healthy adult males with normal renal function. imipenem- cilastatin- relebactam ( imi- rel) is a novel β- lactam- β- lactamase inhibitor combination recently approved for the treatment of complicated urinary tract infections ( cutis) and complicated intraabdominal infections ( ciais). imipenem, cilastatin, and relebactam is a combination medicine that is used to treat complicated infections of the urinary tract ( bladder and kidneys) or infections within the stomach area ( abdomen). both relebactam- containing regimens were well tolerated. imipenem- cilastatin- relebactam ( imi- rel) was granted us food and drug administration ( fda) approval on j, for the treatment of complicated intra- abdominal infections ( ciais) and complicated urinary tract infections ( cutis) in patients 18 years of age or older who have limited or no alternative treatment options available. 5 grams ( imipenem 200mg, cilastatin 200mg, and relebactam 100mg) every 6 hours end stage renal.
v) is given intravenously and is a combination of a broad- spectrum carbapenem antibiotic ( imipenem) ; an inhibitor of dehydropeptidase- i, the renal enzyme that metabolises and inactivates imipenem ( cilastatin) ; and a beta- lactamase inhibitor ( relebactam). directions for administration manufacturer advises for intravenous infusion, dilute to a concentration of 5 mg ( as imipenem) / ml with sodium chloride 0. the severity and location of infection, as well as clinical response, should guide the duration of therapy. comparison of treatment outcomes between analysis populations in the restore- imi 1 phase 3 trial of imipenem- cilastatin- relebactam versus colistin plus imipenem- cilastatin in patients with imipenem- nonsusceptible bacterial infections. imipenem, cilastatin, and relebactam ( intravenous route).
25 g ( imipenem 500 mg, cilastatin 500 mg, and relebactam 250 mg) for adult patients with creatinine clearance of 90 ml/ min or greater the recommended duration of treatment is 4 imipenem cilastatin relebactam days to 14 days. seizures and other central nervous system ( cns) adverse reactions: cns adverse reactions, such as seizures, confusional states, and myoclonic activity, have been reported during treatment with imipenem/ cilastatin, a component of recarbrio, especially when recommended dosages of imipenem were exceeded. imipenem with cilastatin and relebactam ( recarbrio, merck sharp & dohme b. imipenem- cilaststin ( primaxin) has been available for decades, but imipenem- cilastatin- relebactam is a new product is the first fda- approved product to include relebactam relebactam can restore the activity of imipenem- cilastatin in resistant organisms, including some carbapenem- resistant klebsiella and pseudmonas. cilastatin limits the renal metabolism of imipenem and does not have antibacterial activity. imipenem/ cilastatin/ relebactam, sold under the brand name recarbrio, is a fixed- dose combination medication used as an antibiotic. types: human & animal cell lines, primary & tumor cell line.
imipenem/ cilastatin, sold under the brand name primaxin among others, is an antibiotic useful for the treatment of a number of bacterial infections. 9% ( preferably) or glucose 5% ; give intermittently over 30 minutes. prospective, randomized, double- blind, phase 2 dose- ranging study comparing efficacy and safety of imipenem/ cilastatin plus relebactam with imipenem/ cilastatin alone in patients with complicated urinary tract infections. 25 grams ( imipenem 500 mg/ cilastatin 500 mg/ relebactam 250 mg) to. see site for clinical data, adverse reactions, and full pi. it is administered via intravenous injection. for patients with renal impairment, prepare a reduced dose by preparing 100 ml of solution containing 1. imipenem/ cilastatin: when administered alone, imipenem is metabolized in the kidneys by dehydropeptidase, resulting in low imipenem urine levels; cilastatin, an inhibitor imipenem cilastatin relebactam of this enzyme,. 25 grams ( imipenem 500 mg, cilastatin 500 mg, and relebactam 250 mg) administered by intravenous ( iv) infusion over 30 minutes every 6 hours in patients 18 years of age and older with creatinine clearance ( clcr) of 90 ml/ min or greater. imipenem, cilastatin, and relebactam is also used to treat pneumonia ( a lung infection) caused by being in a hospital or using a ventilator. the recommended dosage of recarbrio is 1.
imipenem/ cilastatin and relebactam) ( mg) b. it is made from a combination of imipenem and cilastatin. chemicals for research & pharma industry. food and drug administration has approved recarbrio ( imipenem, cilastatin and relebactam), an antibacterial drug product to treat adults with complicated urinary tract infections ( cuti. it is usually given every 6 hours for 4 to 14 days, or as long your doctor recommends treatment. imipenem is a penem antibacterial drug, cilastatin sodium is a renal dehydropeptidase inhibitor, and relebactam is a beta lactamase inhibitor. imipenem is a penem antibacterial drug, cilastatin sodium is a renal dehydropeptidase inhibitor, and relebactam is a beta- lactamase inhibitor. this medicine is also used to treat hospital- acquired and ventilator- associated bacterial pneumonia.
imipenem 500 mg + relebactam 250 mg + cilastatin 500 mg as a fdc administered intravenously ( iv) every 6 hours for a minimum of 7 days, up to 14 days.